Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Withdrawn before enrolling · Phase 2
Conditions studied: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
In brief
The purpose of this study is to see if continued nivolumab with the addition of ipilimumab plus hypo-fractionated stereotactic radiation (sTR) of a single lesions results in partial or complete responses in patients with metastatic ccRCC who fail initial treatment with single agent nivolumab.
Key facts
- Study ID
- NCT03149159
- Run by
- Medical University of South Carolina
- People needed
- 0
- Starts
- 2018-04-01
- Expected to finish
- 2018-04-01
- Last updated by the study team
- 2018-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed diagnosis of metastatic ccRCC.
- Age 18 years and older
- ECOG 0-1
- Progressive disease after treatment with single-agent nivolumab
- Life expectancy at least 3 months
- Presence of measurable disease per RECIST 1.1 criteria
- Presence of a metastatic lesion greater than 1 cm in size that is amenable to radiation treatment
- Adequate organ system function
- WOCBP and men who are sexually active with WOCBP must agree to use appropriate method(s) of contraception.
You may not qualify if…
- Patients are excluded if they have active brain metastases or leptomeningeal metastases (exceptions outlined in the protocol).
- Active, known or suspected autoimmune disease, such as systemic lupus erythematosus, that require treatment with immune suppressing drugs.
- Note: Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
- Presence of a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of study drug administration.
- Note: Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Unstable angina or uncontrolled congestive heart failure
- Uncontrolled hypercalcemia
- Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Presence of other malignant diseases, except non-melanoma skin care
- History of allergy to study drug components.
- History of severe hypersensitivity reaction to any monoclonal antibody.
- Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days of registration.
- Women must not be pregnant or breastfeeding. WOCBP must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to registration.
- Any other medical condition for which treatment with ipilimumab or nivolumab would be medically contraindicated
Where it is running
- Medical University of South Carolina — Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.